In pancreatic cancer, after neoadjuvant chemotherapy, the median OS of patients with a high CD8+/FOXP3+ lymphocyte ratio was longer than that of patients with a low CD8+/FOXP3+ lymphocyte ratio (p=0.01) (44). This evidence concerns the gene FOXP3 and pancreatic neoplasm.